Knight Therapeutics Inc
(GUD.TO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 371,304 | 328,199 | 293,563 | 243,478 | 199,519 |
| Cost of Goods | 196,899 | 175,547 | 155,502 | 128,066 | 117,829 |
| Gross Profit | 174,405 | 152,652 | 138,061 | 115,412 | 81,690 |
| Operating Expenses | 167,008 | 146,282 | 155,121 | 128,244 | 111,690 |
| Operating Income | 7,397 | 6,370 | -17,060 | -12,832 | -30,000 |
| Interest Expense | 9,223 | 12,488 | 6,600 | 3,618 | 3,398 |
| Other Income | 3,878 | -15,870 | -20,300 | 23,140 | 65,483 |
| Pre-tax Income | 2,052 | -21,988 | -43,960 | 6,690 | 32,085 |
| Income Tax | -2,280 | -5,153 | -14,068 | -8,985 | 325 |
| Net Income Continuous | 4,332 | -16,835 | -29,892 | 15,675 | 31,760 |
| Minority Interests | N/A | N/A | N/A | 0 | 10,307 |
| Net Income | $4,332 | $-16,835 | $-29,892 | $15,675 | $42,067 |
| EPS Basic Total Ops | 0.04 | -0.16 | -0.26 | 0.13 | 0.32 |
| EPS Basic Continuous Ops | 0.04 | -0.16 | -0.26 | 0.13 | 0.32 |
| EPS Diluted Total Ops | 0.04 | -0.16 | -0.26 | 0.13 | 0.32 |
| EPS Diluted Continuous Ops | 0.04 | -0.16 | -0.26 | 0.13 | 0.32 |
| EBITDA(a) | $64,384 | $40,897 | $25,261 | $58,223 | $67,558 |